ORMAT TECHNOLOGIES, INC. (ORA) /
The cash flow of ORMAT TECHNOLOGIES, INC. over the past 10 years
Chart ORMAT TECHNOLOGIES, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, ORMAT TECHNOLOGIES, INC.'s operating cash flow was $335.1M and its capital expenditures $619.78M, leaving free cash flow of -$284.68M. Free cash flow was below zero in all 9 years shown. It ranged from -$308.98M in fiscal 2023 to -$13.66M in fiscal 2017. Capital expenditures were highest in fiscal 2025, at $619.78M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $335.1M | $619.78M | -$284.68M |
| 2024ended Dec 31, 2024 | $410.92M | $487.68M | -$76.76M |
| 2023ended Dec 31, 2023 | $309.4M | $618.38M | -$308.98M |
| 2022ended Dec 31, 2022 | $280.97M | $563.48M | -$282.5M |
| 2021ended Dec 31, 2021 | $258.82M | $419.27M | -$160.45M |
| 2020ended Dec 31, 2020 | $265M | $320.74M | -$55.73M |
| 2019ended Dec 31, 2019 | $236.49M | $279.99M | -$43.49M |
| 2018ended Dec 31, 2018 | $145.82M | $258.52M | -$112.7M |
| 2017ended Dec 31, 2017 | $245.57M | $259.23M | -$13.66M |
| 2016ended Dec 31, 2016 | $159.28M | — | — |
Fiscal years as ORMAT TECHNOLOGIES, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on ORMAT TECHNOLOGIES, INC.
- The revenue of ORMAT TECHNOLOGIES, INC.
- The profitability of ORMAT TECHNOLOGIES, INC.
- The debt of ORMAT TECHNOLOGIES, INC.
- The dividends of ORMAT TECHNOLOGIES, INC.
- All of ORMAT TECHNOLOGIES, INC.'s financials, charted
Companies of a similar size
- ANAUTONATION, INC.
- CGONCG Oncology, Inc.
- LAURLaureate Education, Inc.
- EXPEAGLE MATERIALS INC
- RELYRemitly Global, Inc.
Not investment advice. This page shows what ORMAT TECHNOLOGIES, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.